Sponsored by
by ApotheCom for Otsuka
by TogoRun for Bristol-Myers Squibb
by ApotheCom for Otsuka
The availability of Otsuka’s tolvaptan (Samsca) is stimulating interest in hyponatraemia. Despite being the most common electrolyte disorder in hospitalised patients and associated with poor prognosis and extended hospital stays, hyponatraemia is often under-recognised and poorly managed.
To provide education and guidance to physicians, a pan-European programme was developed to communicate data on the pathophysiology, consequences, diagnosis and treatment of hyponatraemia via an influential network of endocrinologists and nephrologists.
The successful cascade of knowledge through this network has raised the profile of hyponatraemia amongst the medical profession, developed additional experts across Europe and ultimately improved the management of this condition.
Good programme, well planned, very comprehensive: overall, it was of exceptionally high educational value.
For sponsorship opportunities:
Sales Team
sales@pmlive.com
Tel: +44 (0)1372 414200
General event enquiries:
Debbie Tuesley
dtuesley@pmlive.com
Tel: +44 (0)1372 414243